KALA BIO (KALA) Expected to Announce Quarterly Earnings on Tuesday

KALA BIO (NASDAQ:KALA) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect KALA BIO to post earnings of ($6.00) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($21.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.00) by ($15.32).

KALA BIO Trading Up 2.3%

NASDAQ KALA traded up $0.00 on Tuesday, hitting $0.17. 106,121 shares of the company were exchanged, compared to its average volume of 549,629. The company has a market cap of $3.31 million, a P/E ratio of -0.01 and a beta of -2.40. KALA BIO has a 1-year low of $0.11 and a 1-year high of $95.50. The firm has a 50 day moving average of $0.43 and a two-hundred day moving average of $6.89.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on KALA shares. Weiss Ratings restated a “sell (e+)” rating on shares of KALA BIO in a research report on Monday, September 21st. Wall Street Zen upgraded shares of KALA BIO from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, KALA BIO has an average rating of “Sell”.

About KALA BIO

KALA BIO, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases. The company is centered on its mesenchymal stem cell secretome platform, which is designed to deliver multiple naturally occurring growth factors and proteins that may support tissue repair and reduce inflammation.

KALA BIO’s lead investigational product candidate, KPI-012, is being developed for the treatment of persistent corneal epithelial defects, a condition in which the surface of the cornea does not heal properly.